Tridentate hydrazido-hydrazones vanadium complexes. Synthesis, properties and biological activity

• Autorzy: Szklarzewicz Janusz , Jurowska Anna , Hodorowicz Maciej , Matoga Dariusz , Gryboś Ryszard , Filipek Barbara , Sapa Jacek , Głuch-Lutwin Monika , Mordyl Barbara , Kazek Grzegorz

Identyfikatory

DOI

10.5604/01.3001.0013.1485

• Języki publikacji: EN

Abstrakty

EN

Nine new vanadium complexes, with tridentate Schiff base ligand based on 3,5-di-tertbutyl-2-hydroxybenzaldehyde and different hydrazides, are described and characterized. The X-ray crystal structure of complex 8 shows distorted octahedral geometry of vanadium, with ONO ligand in equatorial position. The tridentate Schiff base ligand forms six membered and five-membered chelate rings at the V(V) acceptor center, with the corresponding bite angles being 82.97(9)˚ and 74.48(9)˚. The molecules are gathered by means of intermolecular OH...N hydrogen bond and layered by π...π interactions involving the pyridine and phenolate rings. Such interactions expand the structure along the crystallographic a axis. The complexes were characterized by the elemental analyses, IR, UV-Vis, EPR spectroscopy, cyclic voltammetry, thermogravimetry and magnetic susceptibility measurements. The stabilization role of co-ligands is discussed. The cytotoxicity versus HepG2 hepatocytes and inhibition of human recombinant PTP1B was studied.

Słowa kluczowe

EN

vanadium; complex; Schiff base; structure; hydrazide; biological activity

PL

wanad; kompleks; baza Schiffa; struktura; hydrazyd; aktywność biologiczna

• Wydawca: Państwowa Wyższa Szkoła Zawodowa w Tarnowie
• Czasopismo: Science, Technology and Innovation
• Rocznik: 2019
• Tom: Vol. 4, no. 1
• Strony: 9--20
• Opis fizyczny: Bibliogr. 34 poz., rys., tab.

Twórcy

autor

Szklarzewicz Janusz

• Jagiellonian University, Faculty of Chemistry, Gronostajowa 2, 30-387 Kraków, Poland

autor

Jurowska Anna

• Jagiellonian University, Faculty of Chemistry, Gronostajowa 2, 30-387 Kraków, Poland

autor

Hodorowicz Maciej

• Jagiellonian University, Faculty of Chemistry, Gronostajowa 2, 30-387 Kraków, Poland

autor

Matoga Dariusz

• Jagiellonian University, Faculty of Chemistry, Gronostajowa 2, 30-387 Kraków, Poland

autor

Gryboś Ryszard

• Jagiellonian University, Faculty of Chemistry, Gronostajowa 2, 30-387 Kraków, Poland

autor

Filipek Barbara

• Jagiellonian University Medical College, Pharmacy, Medyczna 9, 30-001 Kraków, Poland

autor

Sapa Jacek

• Jagiellonian University Medical College, Pharmacy, Medyczna 9, 30-001 Kraków, Poland

autor

Głuch-Lutwin Monika

• Jagiellonian University Medical College, Pharmacy, Medyczna 9, 30-001 Kraków, Poland

autor

Mordyl Barbara

• Jagiellonian University Medical College, Pharmacy, Medyczna 9, 30-001 Kraków, Poland

autor

Kazek Grzegorz

• Jagiellonian University Medical College, Pharmacy, Medyczna 9, 30-001 Kraków, Poland

Bibliografia

• 1. Rehder D. Implications of vanadium in technical applications and pharmaceutical issues. Inorganica Chimica Acta. 2017; 455:378-389.
• 2. Azza AA. Synthesis and spectroscopic studies on ternary bis-Schiff-base complexes having oxygen and/or nitrogen donors. Journal of Coordination Chemistry. 2006; 59:157-176.
• 3. Pessoa JC, Etcheverry S, Gambino D. Vanadium compounds in medicine. Coordination Chemistry Review. 2015; 301-302:24-48.
• 4. Dhar DN, Taploo CL. Schiff-bases and their applications. Journal of Scientific and Industrial Research. 1982; 41:501-506.
• 5. Jia Y, Li J. Molecular Assembly of Schiff Base Interactions: Construction and Application. Chemical Review. 2015; 115:1597-1621.
• 6. Przybylski P, Huczynski A, Pyta K, Brzezinski B, Bartl F. Biological properties of Schiff bases and azo derivatives of phenols. Current Organic Chemistry. 2009; 13:124-148.
• 7. Ebrahimipour SY, Sheikhshoaie I, Kautz AC, Ameri M, Pasban-Alibadi F, Rudbari HA, Bruno G, Janiak Ch. Mono-and dioxido-vanadium (V) complexes of a tridentate ONO Schiff base ligand: Synthesis, spectral characterization, X-ray crystal structure, and anticancer activity. Polyhedron. 2015; 93:99-105.
• 8. Zamarin D. Vanadium: A Panacea for Resistance to Oncolytic Immunotherapy? Molecular Therapy. 2018; 26:9-12.
• 9. Zabierowski P, Szklarzewicz J, Gryboś R, Modryl B, Nitek W. Assemblies of salen-type oxidovanadium (IV) complexes: substituent effects and in vitro protein tyrosine phosphatase inhibition. Dalton Transactions. 2014; 43:17044-17053.
• 10. Gryboś R, Szklarzewicz J, Jurowska A, Hodorowicz M. Properties, structure and stability of V (IV) hydrazide Schiff base ligand complex. Journal of Molecular Structure. 2018;1171:880-887.
• 11. Ma L, Lu L, Zhu M, Wang Q, Gao F, Yuan C, Wu Y, Xing S, Fu X, Mei Y, Gao X. Dinuclear copper complexes of organic claw: potent inhibition of protein tyrosine phosphatases. Journal of Inorganic Biochemistry. 2011; 105:1138-1147.
• 12. Wang Q, Zhu M, Lu L, Yuan C, Xing S, Fu X. Potent inhibition of protein tyrosine phosphatases by quinquedentate binuclear copper complexes: synthesis, characterization and biological activities. Dalton Transactions. 2011; 40:12926-12934.
• 13. Lu L, Zhu M. Protein tyrosine phosphatase inhibition by metals and metal complexes. Antioxidants and Redox Signaling. 2014; 20:2210-2224.
• 14. Thompson KH, Orvig C. Vanadium in diabetes: 100 years from Phase 0 to Phase I. Journal of Inorganic Biochemistry. 2006; 100:1925-1935.
• 15. Domingo JL, Gomez M, Sanchez DJ, Llobet JM, Keen CL. Toxicology of vanadium compounds in diabetic rats: the action of chelating agents on vanadium accumulation. Molecular and Cellular Biochemistry. 1995; 153:233–240.
• 16. Domingo JL. Vanadium and tungsten derivatives as antidiabetic agents. Biological Trace Element Research. 2002; 88:97–112.
• 17. Gruzewska K, Michno A, Pawelczyk T, Bielarczyk H. Essentiality and toxicity of vanadium supplements in health and pathology. Journal of Physiology and Pharmacology. 2014; 65:603-611.
• 18. Evangelou AM. Vanadium in cancer treatment. Critical Reviews in Oncology/Hematology. 2002; 42:249-265.
• 19. Llobet JM, Domingo JL. Acute toxicity of vanadium compounds in rats and mice. Toxicology Letters. 1984; 23:227-231.
• 20. Srivastava AK. Anti-diabetic and toxic effects of vanadium compounds. Molecular and Cellular Biochemistry. 2000; 206:177-182.
• 21. Reul BA, Amin SS, Buchet JP, Ongemba LN, Crans DC, Brichard SM. Br. Effects of vanadium complexes with organic ligands on glucose metabolism: a comparison study in diabetic rats. British Journal of Pharmacology. 1999; 126:467-477.
• 22. Fujimoto S, Fujii K, Yasui H, Matsushita R, Takada J, Sakurai H. Long-term acting and orally active vanadyl-methylpicolinate complex with hypoglycemic activity in streptozotocin-induced diabetic rats. Journal of Clinical Biochemistry and Nutrition. 1997; 23:113–129.
• 23. Halevas E, Tsave O, Yavropoulou MP, Hatzidimitriou A, Yovos JG, Psycharis V, Gabriel C, Salifoglou A. Design, synthesis and characterization of novel binary V (V)-Schiff base materials linked with insulin-mimetic vanadium-induced differentiation of 3T3-L1 fibroblasts to adipocytes. Structure–function correlations at the molecular level. Journal of Inorganic Biochemistry. 2015; 147:99-115.
• 24. Sugiyama H, Matsugo S, Misu H, Takamura T, Kaneko S, Kanatani Y, Kaido M, Mihara C, Abeywardana N, Sakai A, Sato K, Miyashita Y, Kanamori K. Regulation of the physiological effects of peroxidovanadium (V) complexes by the electronic nature of ligands. Journal of Inorganic Biochemistry. 2013; 121:66-76.
• 25. Dümmling S, Eichhorn E, Schneider S, Speiser B, Würde M. Recycling of the Supporting Electrolyte Tetra(n-butyl)ammonium Hexafluorophosphate from Used Electrolyte Solutions. Current Separations. 1996; 5:53-56.
• 26. Gryboś R, Paciorek P, Szklarzewicz J, Matoga D, Zabierowski P, Kazek G. Novel vanadyl complexes of acetoacetanilide: Synthesis, characterization and inhibition of proteintyrosine phosphatase. Polyhedron. 2013;49:100-104.
• 27. Sutradhar M, Martins LM, Carabineiro SA, Guedes da Silva MFC, Buijnsters JG, Figueiredo JL, Pombeiro AJL. Oxidovanadium (V) Complexes Anchored on Carbon Materials as Catalysts for the Oxidation of 1‐Phenylethanol. Chem.Cat.Chem. 2016;8:2254-2266.
• 28. Szklarzewicz J, Jurowska A, Hodorowicz M, Gryboś R, Matoga D. Role of co-ligand and solvent on properties of V(IV) oxido complexes with ONO Schiff bases. Journal of Molecular Structure. Under Review. 2018.
• 29. Sheldrick GM. SHELXT - Integrated space-group and crystal-structure determination. Acta Crystallographica Section A Foundations and Advances. 2015; 71:3-8.
• 30. Sheldrick GM. Crystal structure refinement with SHELXL. Acta Crystallographica Section C Structural Chemistry. 2015; 71:3-8.
• 31. Brandenburg K, Putz H. DIAMOND. Crystal Impact GbR, Bonn, Germany. 2005.
• 32. Tsiamis C, Voulgaropoulos B, Charistos D, Voutsas GP, Kavounis C. Ligand reactivity, substituent effects and solvent interactions in the spectra and structure of some oxovanadium (V) chelates with Schiff bases. Proof for dimeric species. Polyhedron. 2000; 19:2003-2010.
• 33. Diamantis AA, Frederiksen JM, Salam MA, Snow MR, Tiekink ERT. Structures of 2 Vanadium (V) Complexes With Tridentate Ligands. Australian Journal of Chemistry. 1986; 39:1081-1088.
• 34. Wang W, Wang X, Liu HX, Tan MY. Synthesis, characterization and crystal structure of an oxovanadium (V) complex with the Schiff base N-benzoylacetone-M-chlorobenzoylhydrazone. Journal of Coordination Chemistry 1995; 36:49-55.

Uwagi

Opracowanie rekordu w ramach umowy 509/P-DUN/2018 ze środków MNiSW przeznaczonych na działalność upowszechniającą naukę (2019).